Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Tracon Pharmaceuticals, Inc. (TCON) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/14/2023 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update San Diego, CA – August 14, 2023 – TRACON Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. “We were pleased to collect the arbitration award of $22M, the initial net proceeds of which extend our cash runway into early 2024 and past expected full accrual of the ENVASARC pivotal trial,” said Charles Th..."
07/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of the ENVASARC Pivotal Trial San Diego, CA – July 11, 2023 – TRACON Pharmaceuticals , a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has collected the previously announced arbitration award from I-Mab Biopharma. “We are pleased to collect the award. As we previously announced in April, the net proceeds extend our cash runway into early 2024 and past expected full accrual of the ENVASARC pivotal trial,” said C..."
06/09/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/02/2023 8-K Unregistered Sales of Equity Securities  Interactive Data
05/04/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
04/06/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
03/31/2023 8-K Other Events  Interactive Data
03/15/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/09/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Form of Pre-Funded Warrant to Purchase Common Stock",
"Securities Purchase Agreement, by and between TRACON Pharmaceuticals, Inc. and the purchaser listed on Exhibit A thereto"
03/08/2023 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update"
01/06/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Corporate Presentation, dated January 2023"
12/30/2022 8-K Quarterly results
12/27/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/14/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
09/30/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS"
09/06/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Warrant to Purchase Common Stock",
"Loan and Security Agreement by and among the Company, each other party thereto as a borrower from time to time, the lenders from time to time party thereto and Runway Growth Finance Corp."
08/26/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
08/10/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
06/21/2022 8-K/A Quarterly results
06/21/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update - Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22"
01/05/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Corporate Presentation, dated January 2022"
12/27/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial Pre-specified Interim Analysis Concluded with Recommendation to Continue the ENVASARC Trial"
11/03/2021 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy